Evidence that FMC7 is a human B cell differentiation antigen.
FMC7 is a 105-kDa B cell restricted antigen which is expressed on about 50% of adult human peripheral blood B cells. Seven to ten days following booster immunization with tetanus toxoid, peripheral blood contains a small population of B cell blasts with an increased density of FMC7. The majority of anti-tetanus toxoid antibody secreting cells (both IgM and IgG) are however found in FMC7- B cells. These data indicate that upon in vivo B cell activation FMC7 expression initially increases. B cells involved in antibody secretion have lost the FMC7 determinant.
Department of Immunology, University Hospital for Children and Youth, Het Wilhelmina Kinderziekenhuis, Utrecht, The Netherlands.
G T
GT
Rijkers
I
I
Dollekamp
B J
BJ
Zegers
D018951:Antigens, CD20; D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis*; D002469:Cell Separation; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations / Q000008:administration & dosage; D005434:Flow Cytometry; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D010567:Pertussis Vaccine / Q000008:administration & dosage; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage; D013745:Tetanus Toxoid / Q000008:administration & dosage; D017778:Vaccines, Combined
D018951:Antigens, CD20; D000944:Antigens, Differentiation, B-Lymphocyte; C051021:DTPP vaccine; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D007075:Immunoglobulin M; D010567:Pertussis Vaccine; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid; D017778:Vaccines, Combined